Recent advances of circulating biomarkers with potential diagnostic, prognostic, and therapeutic value in pancreatic cancer: Limitations of clinical application

IF 2.9 4区医学 Q2 PATHOLOGY

Pathology, research and practice Pub Date : 2025-05-27 DOI:10.1016/j.prp.2025.156045

Zahra Yousefli , Nilofar Rafiee , Tanin Nourollahian , Amirreza Alipour , Zahra Haghshenas , Muhammad Islampanah , Majid Khazaei , Hamid Fiuji , Seyed Mahdi Hassanian , Gordon A. Ferns , Elham Nazari , Amir Avan

{"title":"Recent advances of circulating biomarkers with potential diagnostic, prognostic, and therapeutic value in pancreatic cancer: Limitations of clinical application","authors":"Zahra Yousefli , Nilofar Rafiee , Tanin Nourollahian , Amirreza Alipour , Zahra Haghshenas , Muhammad Islampanah , Majid Khazaei , Hamid Fiuji , Seyed Mahdi Hassanian , Gordon A. Ferns , Elham Nazari , Amir Avan","doi":"10.1016/j.prp.2025.156045","DOIUrl":null,"url":null,"abstract":"<div><div>Several genetic and immunologic biomarkers have shown promise in detecting pancreatic cancer, predicting its progression, monitoring the treatment, and evaluating responses. This review provides a comprehensive overview of recent advancements in biomarker discovery and liquid biopsy for pancreatic cancer. We summarized the biomarkers with prognostic, diagnostic, and therapeutic value, highlighting their individual and combined utility in pancreatic cancer. Moreover, the clinical value of the biomarkers remains to be fully established, and this review discusses the current limitations and complexities associated with these biomarkers and their clinical interpretation. The future direction of novel approaches is discussed, which could shed light on early diagnosis and monitoring of pancreatic cancer. Given the low sensitivity and the impact of co-morbidities on biomarker levels, no single biomarker is sufficient for detection, and establishing an appropriate approach that consists of conventional and non-conventional biomarkers is crucial to obtaining a standardized diagnostic method.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156045"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology, research and practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0344033825002389","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Several genetic and immunologic biomarkers have shown promise in detecting pancreatic cancer, predicting its progression, monitoring the treatment, and evaluating responses. This review provides a comprehensive overview of recent advancements in biomarker discovery and liquid biopsy for pancreatic cancer. We summarized the biomarkers with prognostic, diagnostic, and therapeutic value, highlighting their individual and combined utility in pancreatic cancer. Moreover, the clinical value of the biomarkers remains to be fully established, and this review discusses the current limitations and complexities associated with these biomarkers and their clinical interpretation. The future direction of novel approaches is discussed, which could shed light on early diagnosis and monitoring of pancreatic cancer. Given the low sensitivity and the impact of co-morbidities on biomarker levels, no single biomarker is sufficient for detection, and establishing an appropriate approach that consists of conventional and non-conventional biomarkers is crucial to obtaining a standardized diagnostic method.

查看原文本刊更多论文

具有胰腺癌潜在诊断、预后和治疗价值的循环生物标志物的最新进展：临床应用的局限性

一些遗传和免疫生物标志物在检测胰腺癌、预测其进展、监测治疗和评估反应方面显示出了希望。本文综述了胰腺癌生物标志物发现和液体活检的最新进展。我们总结了具有预后、诊断和治疗价值的生物标志物，强调了它们在胰腺癌中的个体和联合应用。此外，生物标志物的临床价值仍有待充分确定，本综述讨论了目前与这些生物标志物相关的局限性和复杂性及其临床解释。讨论了新方法的未来发展方向，为胰腺癌的早期诊断和监测提供了新的思路。考虑到低灵敏度和共病对生物标志物水平的影响，没有单一的生物标志物足以检测，建立一个由传统和非传统生物标志物组成的适当方法对于获得标准化的诊断方法至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathology, research and practice 医学-病理学

CiteScore

5.00

自引率

3.60%

发文量

405

审稿时长

24 days

期刊介绍： Pathology, Research and Practice provides accessible coverage of the most recent developments across the entire field of pathology: Reviews focus on recent progress in pathology, while Comments look at interesting current problems and at hypotheses for future developments in pathology. Original Papers present novel findings on all aspects of general, anatomic and molecular pathology. Rapid Communications inform readers on preliminary findings that may be relevant for further studies and need to be communicated quickly. Teaching Cases look at new aspects or special diagnostic problems of diseases and at case reports relevant for the pathologist''s practice.